ICT STRATEGIC PLANNING AT PUBLIC HIGHER EDUCATIONAL ORGANIZATIONS: BUILDING AN APPROACH THROUGH ACTION RESEARCH AT UNIRIO

Este artigo apresenta como principal contribuição a descrição do processo e experiência de formulação de planejamento estratégico de Tecnologia da Informação e Comunicação (PDTIC) em uma Instituição Federal de Ensino Superior (IFES). A Pesquisa-Ação foi o método científico utilizado e as etapas do desenvolvimento da pesquisa são narradas. São apresentados os instrumentos construídos para levantamento das necessidades organizacionais, o formulário para diagnóstico institucional, as adaptações indicadas para o modelo de planejamento estratégico do SISP requerido pelos órgãos de gestão, assim como as reflexões sobre o processo de elaboração do PDTIC neste contexto. O planejamento estratégico de ICT resultante deste trabalho demonstra a viabilidade de utilização e adaptação do modelo de planejamento estratégico do SISP, permitindo a efetiva construção do planejamento estratégico de ICT em contextos similares.This paper's main contribution is the description of the process and experience in developing Information and Communication Technology strategic planning at a Brazilian public higher education institution. Action research was used as the scientific method and each of its research steps are presented. It also presents the instruments that were built for assessing organizational needs, the institutional diagnosis form, the required adaptations in the SISP ICT strategic planning model, as well as the reflections about the ICT strategic development process for this particular organizational context. The results evidence the feasibility of use and adaptability of the SISP ICT strategic planning model, enabling the effective ICT strategic development in similar contexts

Síndrome do coração Pós-feriado: pacientes acometidos por arritmia cardíaca em detrimento do consumo exagerado de álcool: Post Holiday coração Syndrome: patients suffered by cardiac arrhythmia to the detriment of exaggerated alcohol consumption

INTRODUÇÃO: O álcool é conhecido por beneficiar o sistema cardiovascular com a ativação do sistema fibrinolítico, redução da agregação de plaquetas e aperfeiçoamento do perfil lipídico, entre outros mecanismos, quando consumido em doses moderadas. Todavia, seu uso de maneira abusiva culmina em patologias graves que podem evoluir para a morte, como a hipertensão arterial, a cardiomiopatia alcoólica, a arritmia cardíaca e até a “Síndrome do Coração Pós Feriado” ou do inglês, “Holiday Heart Syndrome”. OBJETIVOS: O presente estudo tem como objetivo delinear sobre a Síndrome do Coração Pós Feriado, transpassando por suas características clínicas, repercussões eletrofisiológicas, diagnóstico e manejo terapêutico. MATERIAIS E MÉTODOS: Dessa forma, o presente trabalho realizou uma revisão sistemática qualitativa, realizado no período entre julho e agosto de 2022, através de artigos das bases de dados Biblioteca Virtual em Saúde (BVS) e United States National Library of Medicine (PubMed). RESULTADOS E DISCUSSÃO: A interação do álcool no organismo está diretamente relacionada com o sistema nervoso autônomo do indivíduo, gerando um estado de desequilíbrio autonômico, assim há alterações elétricas, como acréscimo da frequência cardíaca, gerando um estado de taquicardia. A principal patologia encontrada em questão foi a taquicardia sinusal, sendo um tipo de arritmia e por conseguinte, notou-se a presença da fibrilação atrial, sendo o excesso no consumo de etanol é causador de aproximadamente 67% dos casos de emergências desta última enfermidade. CONCLUSÃO: Portanto, com base na literatura analisada, observou-se que a ingestão alcoólica aguda age retardando o sistema de condução cardíaco, atua no encurtamento do período refratário e o aumento da atividade simpática, além de aumentar os níveis de catecolaminas circulantes. Por fim, também se evidenciou uma associação entre álcool e fatores de risco, principalmente hipertensão e obesidade e essas patologias aumentam os episódios de fibrilação atrial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Planejamento estratégico de tecnologia da informação e comunicação em instituições federais de ensino superior: construindo uma abordagem através de pesquisa-ação na UNIRIO

This paper´s main contribution is the description of the process and experience in developing Information and Communication Technology strategic planning at a Brazilian public higher education institution. Action research was used as the scientific method and each of its research steps are presented. It also presents the instruments that were built for assessing organizational needs, the institutional diagnosis form, the required adaptations in the SISP ICT strategic planning model, as well as the reflections about the ICT strategic development process for this particular organizational context. The results evidence the feasibility of use and adaptability of the SISP ICT strategic planning model, enabling the effective ICT strategic development in similar contexts.Este artigo apresenta uma experiência de formulação de planejamento estratégico de Tecnologia da Informação e Comunicação (TIC) em uma Instituição Federal de Ensino Superior (IFES). A Pesquisa-Ação foi o método científico utilizado e as etapas do desenvolvimento da pesquisa são narradas. Os resultados (instrumentos, produtos e reflexões) obtidos são identificados como contribuições tanto para a aplicação do planejamento estratégico em outras IFES, como para a especificação de modelos de planejamento estratégico adequados às particularidades deste contexto organizacional. . A relevância dos resultados deste trabalho para a instituição é comprovada pela elevação do Índice de Governança de TI apurado pelo TCU

A pilot case-control association study of cytokine polymorphisms in Brazilian women presenting with HPV-related cervical lesions

Objective and study design: A case-control study was conducted on 42 Brazilian women presenting with human papilloma virus (HPV) infection and cervical lesion and 87 HPV-negative women to evaluate single nucleotide polymorphisms observed in TNF-alpha, TGF-beta, IL-10, IL-6, and IFN-gamma genes. Results and conclusion: No significant association was observed on the cytokine polymorphisms analyzed in this series. Larger studies using cytokine polymorphisms may be useful for providing further information regarding their influence or not in HPV-related cervical lesions. (C) 2008 Elsevier Ireland Ltd. All rights reserved.FAPESP[97/04490-8]FAPESP[01/02908-2

Enzyme replacement therapy for mucopolysaccharidosis type II: Experience from a Brazilian reference center

Universidade Federal de São Paulo, São Paulo, BrazilUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc